MetaCap

Lakefront Biotherapeutics (LKFT) vs Perrigo (PRGO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Perrigo (PRGO) has outperformed Lakefront Biotherapeutics (LKFT) over the past year, gaining 26.1% versus a gain of 8.6%. Over five years, LKFT leads with a -31.8% price change compared with -57.8% for PRGO. Perrigo is the larger company by market cap ($2.21 billion vs $2.18 billion), about 1.0 times the size.

Perrigo pays a dividend yielding 7.28%, while Lakefront Biotherapeutics does not currently pay one.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LKFT+8.64%PRGO+26.11%
+37%+4%-30%
Nov 21, 20251 yearNov 20, 2026
LKFT-35.27%PRGO-61.25%
+42%-21%-83%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LKFT versus PRGO key metrics
MetricLKFTPRGO
Share price$33.31$15.94
Market cap$2.18B$2.21B
1-day change-0.24%-0.62%
YTD return+1.87%+14.51%
1-year return+8.64%+26.11%
5-year return-31.80%-57.81%
P/E ratio (TTM)2.39—
Forward P/E—6.94
EPS (TTM)$13.94$-12.47
Dividend yield0.00%7.28%
Annual dividend$0.00$1.16
Revenue (latest FY)—$4.25B
Revenue growth (YoY)—-2.75%
Net income (latest FY)—$-1.43B
Gross margin—35.14%
Operating margin—-26.39%
Net margin—-33.51%
52-week high$36.24$17.07
52-week low$25.68$9.23
Distance from 52-week high-8.08%-6.62%
Analyst consensusholdbuy
Avg. price target upside-7.39%+12.92%
Average volume280.49K2.54M
Shares outstanding65.48M138.80M
Employees1968,100
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PRGO has outperformed LKFT by 17.5 percentage points over the past year.
  • Perrigo offers a meaningfully higher dividend yield (7.28% vs 0.00%).

About Lakefront Biotherapeutics

LKFT stock →

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.

Health Care · Biotechnology: Pharmaceutical Preparations · 196 employees

About Perrigo

PRGO stock →

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.

Health Care · Biotechnology: Pharmaceutical Preparations · 8,100 employees

LKFT vs PRGO FAQ

Which is bigger, Lakefront Biotherapeutics or Perrigo?

Perrigo (PRGO) is larger, with a market capitalization of $2.21B compared with $2.18B for Lakefront Biotherapeutics (LKFT).

Which stock has performed better over the past year, LKFT or PRGO?

PRGO returned +26.11% over the past 12 months, compared with +8.64% for LKFT (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Lakefront Biotherapeutics or Perrigo?

Perrigo pays a dividend yielding 7.28%, while Lakefront Biotherapeutics does not currently pay a regular dividend.

Are Lakefront Biotherapeutics and Perrigo in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons